- ISIN
- US90240B1061
- CUSIP
- 90240B106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 15, 2021
Highlights
- Market Cap
- $1.77B
- Enterprise Value
- $1.69B
- EPS (TTM)
- -$2.18
- Gross Profit (TTM)
- -$132.00K
- EBITDA (TTM)
- -$129.69M
- Year Range
- $8.98 - $40.65
- Target Price
- $50.50
- ROA (TTM)
- -31.82%
- ROE (TTM)
- -33.83%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TYRA Performance Chart
Tyra Biosciences, Inc. (TYRA) is up 9.0% since the beginning of the year. At $29 per share, TYRA is trading 29.5% below its 52-week high of $41.
Loading charts...
Returns By Period
Tyra Biosciences, Inc. (TYRA) has returned 9.01% so far this year and 198.54% over the past 12 months.
Tyra Biosciences, Inc.
- 1D
- -5.69%
- 1M
- -15.80%
- YTD
- 9.01%
- 6M
- 37.00%
- 1Y
- 198.54%
- 3Y*
- 25.41%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
TYRA Monthly Returns History
Based on dividend-adjusted daily data since Sep 15, 2021, TYRA's average daily return is +0.14%, while the average monthly return is +2.26%. At this rate, an investment would double in approximately 2.6 years.
Historically, 55% of months were positive and 45% were negative. The best month was Feb 2024 with a return of +49.2%, while the worst month was Dec 2021 at -43.9%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.
On a daily basis, TYRA closed higher 50% of trading days. The best single day was Feb 2, 2024 with a return of +29.3%, while the worst single day was Oct 25, 2024 at -23.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 17.23% | 8.08% | 14.98% | -9.27% | -3.86% | -14.22% | 9.01% | ||||||
| 2025 | 4.03% | -19.02% | -20.58% | 10.75% | -11.65% | 5.16% | 14.21% | 15.92% | 10.42% | 13.22% | 42.42% | 16.53% | 89.14% |
| 2024 | -3.25% | 49.18% | -17.96% | 4.27% | -5.15% | -1.42% | 38.59% | 2.71% | 3.30% | -29.05% | -6.00% | -11.35% | 0.36% |
| 2023 | 39.74% | 24.39% | 21.65% | -11.82% | 2.12% | 17.69% | -12.98% | 2.77% | -9.59% | -15.76% | 0.95% | 18.27% | 82.24% |
| 2022 | -6.82% | -9.61% | -9.70% | -30.19% | -8.57% | 4.69% | 48.95% | -37.93% | 32.98% | -21.27% | 1.30% | 8.42% | -45.98% |
| 2021 | -32.35% | 27.29% | 12.06% | -43.92% | -45.88% |
Benchmark Metrics
Tyra Biosciences, Inc. has an annualized alpha of 19.88%, beta of 1.34, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since September 16, 2021.
- This stock participated in 145.74% of S&P 500 Index downside but only 114.46% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.88%
- Beta
- 1.34
- R²
- 0.08
- Upside Capture
- 114.46%
- Downside Capture
- 145.74%
Return for Risk
Risk / Return Rank
TYRA ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Tyra Biosciences, Inc. (TYRA) and compare them to S&P 500 Index.
| TYRA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.27 | 2.39 | +0.88 |
Sortino ratioReturn per unit of downside risk | 3.90 | 3.25 | +0.64 |
Omega ratioGain probability vs. loss probability | 1.44 | 1.43 | +0.01 |
Calmar ratioReturn relative to maximum drawdown | 7.28 | 3.11 | +4.16 |
Martin ratioReturn relative to average drawdown | 29.17 | 14.38 | +14.78 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Tyra Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Tyra Biosciences, Inc. was 83.22%, occurring on Jun 17, 2022. Recovery took 903 trading sessions.
The current Tyra Biosciences, Inc. drawdown is 27.64%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -83.22%Jun 2022 | 7mo 14d | 3y 7mo | 4y 2moNov 2021 - Jan 2026 |
2021 bear market2021 | -48.23%Oct 2021 | 19d | 29d | 1mo 18dSep 2021 - Nov 2021 |
2026 bear market2026 | -27.64%Jun 2026 | 1mo 27d | — | 1mo 28dApr 2026 - now |
2026 correction2026 | -13.45%Feb 2026 | 14d | 10d | 24dJan 2026 - Feb 2026 |
2026 pullback2026 | -9.38%Mar 2026 | 10d | 1d | 11dMar 2026 - Mar 2026 |
Drawdown Indicators
| TYRA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.22% | -56.78% | -26.44% |
Max Drawdown (1Y)Largest decline over 1 year | -27.64% | -9.10% | -18.54% |
Max Drawdown (3Y)Largest decline over 3 years | -75.32% | -18.90% | -56.42% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -27.64% | 0.00% | -27.64% |
Average DrawdownAverage peak-to-trough decline | -51.08% | -10.72% | -40.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.87% | 1.97% | +4.90% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Tyra Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Tyra Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TYRA in comparison with other companies in the Biotechnology industry. Currently, TYRA has a P/B value of 4.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TYRA
Add Tyra Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TYRA